ICMR in­vests into vac­cine re­search

BioSpectrum (India) - - POLICY AND REGULATORY NEWS -

The In­dian Coun­cil of Med­i­cal Re­search (ICMR) has en­tered into an agree­ment to col­lab­o­rate on vac­cine re­search and de­vel­op­ment with in­ter­na­tional vac­cine de­vel­op­ment or­gan­i­sa­tion In­ter­na­tional Vac­cine In­sti­tute (IVI). Through this part­ner­ship, In­dia will com­mit $5,00,000 (Rs 3.20 crore) an­nu­ally for a stake in IVI—an amount ap­proved dur­ing a cab­i­net meet­ing in Jan­uary.

Un­der its latest Memorandum of Un­der­stand­ing (MoU), ICMR will be fo­cused on re­search and de­vel­op­ment of vac­cines com­bat­ting var­i­ous in­fec­tious dis­eases. Un­der ICMR’s latest part­ner­ship, vac­cine can­di­dates devel­oped in IVI labs could be brought to In­dia and given to one of the com­pa­nies here for fur­ther de­vel­op­ment. IVI may also fa­cil­i­tate fur­ther global test­ing of vac­cine can­di­dates devel­oped in In­dian labs by link­ing de­vel­op­ers here with global part­ners.

The part­ner­ship is fur­ther ex­pected to help with ca­pac­ity build­ing for clin­i­cal tri­als within In­dia as well. The MoU is also ex­pected to help sup­port com­pa­nies like Bharat Biotech, which has com­pleted phase I clin­i­cal tri­als of its chikun­gunya vac­cine and has ex­pressed the need for sup­port in con­duct­ing phase II and III tri­als for the can­di­date.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.